Human papilloma virus (hpv)
Drug research and approvals for human papilloma virus (hpv): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 143 studies of human papilloma virus (hpv) are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 0 approved and 6 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 143
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 143 recruiting on ClinicalTrials.gov ↗- Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve…NCT06926062 · Not applicable · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07576842 · Not applicable · University of California, San Diego · starts Nov 9, 2026
- A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at…NCT07418034 · Phase 2 · University of Maryland, Baltimore · starts Oct 19, 2026
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07925307 · Not applicable · University of California, San Diego · starts Oct 16, 2026
- Developing and Implementing HPV SCREENEDNCT07657104 · Not applicable · Rutgers, The State University of New Jersey · starts Oct 15, 2026
- Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 RwandaNCT07390916 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 15, 2026
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living…NCT07645352 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 15, 2026
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in…NCT07645378 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 15, 2026
- Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV…NCT07468695 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 12, 2026
- A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine…NCT07785843 · Phase 3 · Merck Sharp & Dohme LLC · starts Oct 10, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 23, 2023 | Phase 2a multicenter, randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of topical nitric oxide releasing…NITRIC OXIDE | SANOTIZE RESEARCH & DEVELOPMENT CORP | Closed |
| Feb 25, 2022 | Molecular residual disease interception in locoregionally-advanced high risk hpv+ and hpv- hnscc (meridian)AZD2936 | PRINCESS MARGARET CANCER CENTRE | Ongoing |
| Jan 17, 2018 | A phase 1/1b, multicenter, open-label trial of oncolytic mg1 expressing mutant human papilloma virus (hpv) e6 and e7 (mg1-e6e7), with adenovirus vaccine…AD-E6E7 / MG1-E6E7/ KEYTRUDA | TURNSTONE BIOLOGICS | Closed |
| Jun 10, 2016 | Long term immune memory responses to human papillomavirus (hpv) vaccination following 2 versus 3 doses of quadrivalent hpv vaccineGARDASIL | VACCINE EVALUATION CENTER, UNIVERSITY OF BRITISH COLOMBIA | Pending |
| Apr 16, 2015 | "essai clinique visant a documenter l'immunogenicite et l'innocuite des vaccins gardasil 9 et cervarix administres de facon interchangeable aux jeunes de 9-10…GARDASIL 9/CERVARIX | CENTRE HOSPITALIER UNIVERSITAIRE DE QUEBEC | Pending |
| Apr 24, 2014 | A phase III randomized, international, placebo-controlled, double-blind clinical trial to study the tolerability and immunogenicity of v503, a multivalent…V503 (NONVALENT HPV L1 VLP VACCINE) | Merck & Co. (MSD) | Ongoing |
| Oct 17, 2013 | A phase III clinical trial to study the tolerability and immunogenicity of a 2-dose regimen of v503, a multivalent human papillomavirus (hpv) l1 virus-like…V503 (NONAVALENT HPV L1 VLP VACCINE) | Merck & Co. (MSD) | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 1, 2020 | Human autologous CD4+ and CD8+ T cells engineered ex vivo…Treatment of patients with human papillomavirus (HPV)+ cervical cancer who are human leukocyte antigen (HLA)-A*02+ | Kite Pharma, Inc. | Designated |
| Sep 4, 2014 | Adenovirus serotype-5 (Ad5) vector that contains a modified…Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) | Etubics Corporation | Designated |
| Nov 4, 2013 | live attenuated bioengineered Listeria monocytogenes…Treatment of human papilloma virus-associated head and neck cancer | Ayala Pharmaceuticals, Inc. | Designated |
| Aug 12, 2013 | ADXS11-001Treatment of HPV-positive associated anal cancer | Advaxis, Inc. | Designated |
| Sep 1, 2011 | HPV16 E6/E7 synthetic long peptides vaccineTreatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16. | ISA Therapeutics BV | Designated |
| Jan 12, 2009 | HPV-16 cancer therapeutic trojan peptide vaccineTreatment of HPV-16 expressing head and neck squamous cell carcinoma. | Gliknik, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jun 10, 2015 | Gardasil 9human papillomavirus 9-valent vaccine (recombinant, adsorbed) | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA